
Cytocom in proposed merger with Cleveland BioLabs after SEC filing
FORT COLLINS/ BUFFALO, N.Y. -- New York-based Cleveland BioLabs, Inc. (NASDAQ: CBLI), a biopharmaceutical company developing novel approaches to activate the immune system, filed a registration... Read More
Thursday February 18, 2021 0 comments

Cytocom updates investigational new drug application for phase 2 clinical trial of CYTO-205 for treatment of COVID-19
FORT COLLINS -- Cytocom, Inc. today provided an update regarding its CYTO-200 portfolio of clinical programs. Cytocom said it has submitted an Investigational New Drug (IND) application with... Read More
Tuesday February 16, 2021 0 comments